• Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck

    6 days ago - By Xconomy

    A Roche immunotherapy has won an additional FDA approval as a first-line treatment for non-small lung cancer, bolstering the product's competitive stance versus one from Merck. The FDA approved atezolizumab for adults whose non-squamous non-small cell lung cancer is metastatic, meaning it has spread, and does not have the EGFR or ALK genetic mutations. The regulatory decision covers the treatment in combination with the chemotherapy regimen paclitaxel and carboplatin. Non-small cell lung cancer accounts for approximately 85 percent of all lung cancers, according to the American Cancer...
    Read more ...